DUPIXENT? (DUPILUMAB) APPROVED IN THE U.S. AS FIRST AND ONLY TREATMENT FOR ADOLESCENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS (CRSWNP)

發(fā)布時(shí)間： 2024-09-14 閱讀：212次

分享

September 13, 2024 -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent? (dupilumab) as an add-on maintenance treatment for adolescent patients aged 12 to 17 years with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP).

“This latest approval for Dupixent marks the first time a biologic is specifically indicated for adolescents with chronic rhinosinusitis with nasal polyps, offering them an option beyond current standard of care.” said Brian Foard, Executive Vice President, Head, Specialty Care at Sanofi.

Dupixent has received regulatory approvals in more than 60 countries in one or more indications including certain patients with atopic dermatitis, asthma, CRSwNP, eosinophilic esophagitis, prurigo nodularis, chronic spontaneous urticaria, and chronic obstructive pulmonary disease in different age populations. More than 1,000,000 patients are being treated with Dupixent globally.